- Conditions
- Bacterial Pneumonia
- Interventions
- Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 622 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 35
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Community Acquired Bacterial Pneumonia
- Interventions
- Efficacy of ceftaroline
- Drug
- Lead sponsor
- Albany Medical College
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Albany, New York
- Conditions
- Pneumonia, Bacterial
- Interventions
- Sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 12
- States / cities
- Chula Vista, California • Oceanside, California • Moline, Illinois + 4 more
- Conditions
- Pneumonia, Bacterial
- Interventions
- CAL02, Placebo
- Drug
- Lead sponsor
- Eagle Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Fresno, California • Gainesville, Florida • Chicago, Illinois + 4 more
- Conditions
- Community-acquired Pneumonia, Bacterial Pneumonia
- Interventions
- CMTX-101, Placebo
- Drug
- Lead sponsor
- Clarametyx Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
- Conditions
- Pneumonia, Bacterial, Pneumonia Childhood, Urinary Tract Infections, Soft Tissue Infections, Skin Infections, Community-acquired Pneumonia
- Interventions
- Discharge antibiotic stewardship intervention
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 28 Days to 18 Years
- Enrollment
- 1,131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Salt Lake City, Utah + 1 more
- Conditions
- Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
- Interventions
- Electronic alert, Structured communication of test results
- Behavioral
- Lead sponsor
- Jonathan Baghdadi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Community-acquired Pneumonia, Influenza, COVID-19
- Interventions
- Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
- Drug · Other · Biological + 1 more
- Lead sponsor
- UMC Utrecht
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 11
- States / cities
- Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Pneumonia, Pneumococcal, Vaccines, Pneumococcal
- Interventions
- Urine sample collection
- Procedure
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 782 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
- Conditions
- Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
- Interventions
- all macrolide antibiotics, all beta-lactam antibiotics
- Drug
- Lead sponsor
- CPL Associates
- Other
- Eligibility
- Up to 95 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- Solithromycin, Moxifloxacin
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 863 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 62
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
- Conditions
- Community Acquired Bacterial Pneumonia
- Interventions
- Delafloxacin, Moxifloxacin, Linezolid
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 25
- States / cities
- Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more
- Conditions
- Streptococcus Pneumonia, Haemophilus Influencae, Mycoplasma Pneumonia, Chlamydia Pneumonia
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Community-Acquired Bacterial Pneumonia (CABP)
- Interventions
- Nafithromycin 800 mg 3 days, Nafithromycin 800 mg 5 days, Moxifloxacin 400 mg
- Drug
- Lead sponsor
- Wockhardt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Miami, Florida • Miami Lakes, Florida • Bedford, Massachusetts + 1 more
- Conditions
- Community Acquired Pneumonia
- Interventions
- lefamulin, Moxifloxacin
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 25
- States / cities
- Beverly Hills, California • Fresno, California • Northridge, California + 20 more
- Conditions
- Community-acquired Bacterial Pneumonia
- Interventions
- Solithromycin, Standard of Care
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 2 Months to 17 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
- Conditions
- Community-Acquired Bacterial Pneumonia
- Interventions
- Levofloxacin, CEM-101
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more
- Conditions
- Influenza, Pneumonia
- Interventions
- oseltamivir
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky
- Conditions
- Community Acquired Pneumonia
- Interventions
- Dalbavancin, Linezolid, Linezolid Placebo, Azithromycin
- Drug
- Lead sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Butte, Montana
- Conditions
- Coccidioidomycosis, Pneumonia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 14 Years to 99 Years
- Enrollment
- 651 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 2 more
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Interventions
- Antibiotic
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 34
- States / cities
- Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
- Conditions
- Bacterial Pneumonia
- Interventions
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Pasadena, California • Sacramento, California + 9 more
- Conditions
- Community-acquired Pneumonia
- Interventions
- AON-D21, Placebo
- Drug
- Lead sponsor
- Aptarion Biotech AG
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Community-acquired Pneumonia
- Interventions
- Omadacycline
- Drug
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • San Diego, California • Clearwater, Florida + 7 more